Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 6 of 6 publications.

Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451

Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).

Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.

Chatzi L, Plana E, Pappas A, Alegkakis D, Karakosta P, Daraki V. The metabolic syndrome in early pregnancy and risk of gestational diabetes mellitus. Diabetes Metab. 2009 Dec;35(6):490-4.

Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.

Caro JJ, Ward A, Craig T, Huybrecht K, Arana A, Wait S, Eleftheriou A. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107(3):150-7.